Daewoong Pharmaceutical Co.,Ltd sell "FEXUCLUE®"
Basic Information
395
13
3
4.7(20)
Category
Subcategory & Sub-subcategory
Trade Type
Sell
Product Name
FEXUCLUE®
Details
Manufacturer(s)
Specifications
- Content Uniformity: Complies with USP <905>/Ph. Eur. content uniformity acceptance limits
- Container Closure Integrity: Validated container-closure integrity per USP <1207>
- Particulate Matter: Complies with USP <788> particulate matter limits
Other Information
Additional Description:
FEXUCLUE (fexuprazan) is a novel acid-suppressing agent positioned as best-in-class for its fast onset and potent efficacy, addressing gaps left by conventional PPIs. It launched in Korea in 2022 and the Philippines in 2023, has been approved in Chile and Ecuador, has NDAs under review in China, Brazil, Mexico, Colombia, Peru, Thailand, and Saudi Arabia, among others, and additional dosages and indications remain in development.
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Matched Products & Services
B2B matches based on trade type, category, specifications & price range
Similar Products & Services
Products & Services related to what you're viewing
People Also Viewed
Other products & services viewed by people who looked at this product
Leave your rating & comment